In addition to its known roles in regulating cell survival, inflammation, and cardiac hypertrophy, the transcription factor nuclear factor-kB (NFkB) has been implicated as a maladaptive mediator of cardiac ischemic injury, but the underlying mechanisms remain undefined. Our objective was to assess the contribution of NFkB-p65 to myocardial injury, pathological remodeling, and ventricular dysfunction after myocardial infarction using cardiac-specific knockout mice. Intriguingly, ablation of NFkB-p65 in the heart protected against adverse remodeling and heart failure following myocardial infarction for 2 weeks. NFkB-p65 knockout mice showed reduced cardiac hypertrophy, fibrosis, and pulmonary congestion compared to control mice. Better-preserved cardiac function and less ventricular dilation were also observed in NFkB-p65 knockout mice after MI. NFkB-p65 knockout and control mice were also subjected to acute ischemia/reperfusion (I/R, 60 min ischemia & 24 h reperfusion). Loss of NFkB-p65 also protected the heart against acute I/R damage as evidenced by decreased infarct size. Accumulating evidence has demonstrated that oxidative stress participates in several aspects of cardiac remodeling after myocardial infarction, including loss of cardiomyocytes by apoptosis and necrosis, inflammatory/fibrogenic responses, and hypertrophy. Here, we examined the role of NFkB-p65 in regulating cell survival/death induced by oxidative stress. We showed that NFkB-p65 silencing in mouse embryonic fibroblasts significantly reduced necrotic cell death induced by reactive oxygen species (ROS). Specifically, ablation of p65 prevented cellular uptake of propidium iodide induced by H2O2 or tBHP (tert-Butyl hydroperoxide), as well as the release of HMGB1 (high mobility group box 1) into culture supernatant (a biomarker of necrosis). No changes in apoptosis markers were detected under these conditions, suggesting that NFkB-p65 mediates ROS-induced necrosis, but not apoptosis. These results identified a novel role for NFkB-p65 in mediating myocardial injury and ROS-induced necrosis, suggesting that NFkB-p65 may serve as a therapeutic target for myocardial damage and remodeling following myocardial infarction.